According to new analysis of the Devote study, people with type 2 diabetes and who are administered insulin degludec (Tresiba), of Novo, without severe hypoglycemia (low blood sugar levels) reduce the risk of death.
The risk was four times greater fifteen days after an episode of severe hypoglycemia and twice and a half times higher at any time after it.
The results also showed that daily fluctuations in the blood sugar levels of people with type 2 diabetes are associated with a higher risk of death.These data have been published in the Diabetology magazine.
"The episodes of severe hypoglycemia are not only distressing for patients and potentially dangerous, but are also associated with a higher risk of death," says Bernard Zinman of the Lunenfeld-Tanenbaum Research Institute located in the Mount Sinai hospital in Toronto (Canada), Professor at the University of Toronto and member of the Devote Steering Committee.
"These results highlight the importance of maintaining low variability in blood sugar levels and reducing the risk of severe hypoglycemia when treated with people with type 2 diabetes."
In the Devote study, Insulin Degludec reduced the rate of severe hypoglycemia by 40 percent and the rate of severe night hypoglycemia in 53 percent compared to insulin Glargina U100 in people with type 2 diabetes.
Similar reductions were observed in the Switch 2 study with 51 percent less severe hypoglycemia during the total period of test treatment and a 42 percent reduction in the night hypoglycemia rate in the maintenance period compared to insulin Glargina U100 inPeople with type 2 diabetes.
Studies have also shown that Insulin Degludec provides significantly lower variability in blood sugar levels compared to insulin Glargina U100 and U300.5,6
